This article corrects an earlier version that mistakenly reported that Acacia Technologies subsidiary CombiMatrix licensed the IP.
NEW YORK (GenomeWeb News) — Acacia Research Corporation last week said that Acacia Patent Acquisition Corporation, a wholly owned subsidiary of Acacia Technologies, has acquired rights to patents relating to purifying nucleic acids.
Acacia did not disclose the name of the entity that sold it the IP, but said that the patents “generally relate to methods and equipment used to purify plasmid DNA products.”
The company said the technology could be used to produce "ultrapure pharmaceutical quality nucleic acids for DNA-vaccines and gene therapies” for a variety of diseases.
Financial terms of the agreement were not released.